Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COLOMBE nivolumab + imiquimod in vulvar squamous cell carcinoma
2025-524759-29-00Phase 2Authorised
- Sponsor
- Centre Léon Bérard
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and imiquimod in vulvar squamous cell carcinoma (VSCC), sponsored by Centre Léon Bérard. Primary endpoints: Dose-limiting toxicity during safety run-in and Clinical objective response rate. Planned start Oct 2026; status: authorised.
02
Drugs
nivolumabimiquimod
03
Conditions
vulvar squamous cell carcinoma (VSCC)
Beyond the preview
Go deeper on 2025-524759-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524759-29-00.